Pricing database updated July 12, 2026Methodology v1.0How we score →
Compare Providers
Home / Peptide therapy: evidence and safety
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Written by Dr. Parmis Mojarab, DO·Reviewed by Kim Callender, NP, FNP-BC·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Peptide therapy: evidence and safety

Peptide therapy is marketed aggressively and regulated inconsistently. This hub separates approved uses from research compounds, human evidence from animal data, and legitimate clinical care from research-chemical sales.

Quick answer

Peptides are short chains of amino acids. A few are FDA-approved drugs for specific indications; most sold for anti-aging, recovery or physique are unapproved, sold as 'research chemicals,' and supported mainly by animal data. We grade the evidence honestly and never link to research-chemical sellers.

Explore this topic

Peptide therapy overview

How peptide therapy works and its regulatory reality

BPC-157

Marketed for healing — minimal human evidence

CJC-1295 / Ipamorelin

Growth-hormone secretagogue stack

Sermorelin

GHRH analog with a regulated history

Tesamorelin

FDA-approved for one indication

NAD+

Longevity marketing vs evidence

Peptide safety

Sourcing, purity and injectable risks

Peptide legality

What 'research use only' really means

Sources

  1. U.S. Food and Drug Administration — approval and compounding status.
  2. Primary clinical literature cited on child pages.
  3. Our methodology and source standards.

Spotted an error? Submit a correction.